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Abstract 
Background: Clinical trials continue to be the gold standard for determining the efficacy of novel cancer treatments, 
but they may also expose participants to the potential risks of unpredictable or severe toxicities. The development 
of validated tools that better inform patients of the benefits and risks associated with clinical trial participation can 
facilitate the informed consent process. The design and validation of such instruments are strengthened when we 
leverage the power of pooled data analysis for cancer outcomes research.
Main body: In a recent study published in the Journal of Clinical Oncology entitled “Determinants of early mortal‑
ity among 37,568 patients with colon cancer who participated in 25 clinical trials from the adjuvant colon cancer 
endpoints database,” using a large pooled analysis of over 30,000 study participants who were enrolled in clinical trials 
of adjuvant therapy for early‑stage colon cancer, we developed and validated a nomogram depicting the predictors 
of early cancer mortality. This database of pooled individual‑level data allowed for a comprehensive analysis of poor 
prognostic factors associated with early death; furthermore, it enabled the creation of a nomogram that was able to 
reliably capture and quantify the benefit‑to‑risk profile for patients who are considering clinical trial participation. This 
tool can facilitate treatment decision‑making discussions.
Conclusion: As China and other Asian countries continue to conduct oncology clinical trials, efforts to collate 
patient‑level information from these studies into a large data repository should be strongly considered since pooled 
data can increase future capacity for cancer outcomes research, which, in turn, can enhance patient‑physician discus‑
sions and optimize clinical care.
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Background
The development of novel cancer diagnostics and thera-
peutics is largely dependent on valuable insights gained 
from randomized controlled clinical trials. Although 
clinical trials remain the gold standard for determining 
the overall efficacy, feasibility, and safety of these new 
interventions, they may also expose patients to unnec-
essary harms since new treatments inherently carry the 
risk of unpredictable or severe adverse events. Therefore, 
the benefits and risks of clinical trials must be carefully 
balanced, and patients who are considering study partici-
pation should engage in thorough discussions with their 
physicians before providing informed consent. Similarly, 
clinicians must weigh the pros and cons of clinical trials 
to ensure that study participation does not pose excessive 
harms to patients.
To date, determining whether a patient is suitable for 
clinical trials has been primarily dependent on a com-
bination of patient preference and clinician judgement. 
However, this approach can be potentially unreliable, 
especially for specific subpopulations that are either older 
or frailer. The development of readily accessible and user-
friendly tools that objectively inform patients of the ben-
efits and risks associated with clinical trial participation 
can facilitate the informed consent process as well as the 
patient-physician conversation. The design and validation 
of such instruments are strengthened when we leverage 
the power of pooled data analysis for cancer outcomes 
research.
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The use of large databases of pooled patient data has 
already made it possible to address several important and 
clinically relevant research questions. Data from real-
world, population-based settings [e.g., the British Colum-
bia Cancer Agency (BCCA)] and clinical trial settings 
[e.g., Adjuvant Colon Cancer Endpoints (ACCENT)] 
have been previously interrogated to generate high-pro-
file articles that successfully examined the effect of sys-
temic therapy on overall and cancer-specific survival as 
well as the effect of various clinical and pathologic fac-
tors, such as age, race, and stage, on outcomes [1–3].
Whereas previous studies have largely explored prog-
nostic factors for early mortality among phase I study 
participants, similar studies to identify prognostic factors 
among phase III study participants have not been con-
ducted. Most prior research was further limited by small 
sample sizes or significant heterogeneity in the pooled 
cohorts [4, 5]. Thus, we saw an opportunity to use the 
ACCENT database to identify prognostic factors related 
to early mortality in phase III study participants. Specifi-
cally, the ACCENT database represents a large pooled 
repository of individual-level data from patients who had 
previously participated in phase III adjuvant colon cancer 
clinical trials. Leveraging this comprehensive database, 
we were able to provide insights into prognostic factors 
for early mortality in phase III study participants.
Main body
In our recent Journal of Clinical Oncology article entitled 
“Determinants of early mortality among 37,568 patients 
with colon cancer who participated in 25 clinical trials 
from the adjuvant colon cancer endpoints database” [6], 
we reported the results of a study that characterized the 
determinants of early mortality in a large cohort of early-
stage colon cancer patients who had participated in prior 
adjuvant clinical trials. This study was conducted because 
the factors associated with early death after surgery and 
adjuvant chemotherapy are poorly defined. Therefore, we 
conducted a pooled analysis of over 30,000 patients from 
25 randomized clinical trials of adjuvant systemic ther-
apy. Using multivariate logistic regression models and 
controlling for confounders, we successfully developed 
and validated a nomogram for 6-month mortality.
We found that early mortality was very low: 0.3% at 
30  days, 0.6% at 60  days, 0.8% at 90  days, and 1.4% at 
6  months [6]. Consistent with other studies [7–9], our 
prognostic analyses showed that advanced age, male gen-
der, worse performance status, and higher tumor stage 
and grade predicted a greater likelihood of early mor-
tality, whereas treatment received was not significantly 
associated with early mortality. Our findings under-
scored the observation that early mortality was generally 
uncommon, but it was more frequently seen in specific 
subsets of patients, such as those who were older and 
frailer. This highlights the importance of tools that can 
better clarify the benefit-to-risk ratio to patients who are 
considering clinical trial participation. The nomogram 
developed from our analysis has been validated and cali-
brated to serve as a potentially effective instrument that 
can guide and enhance treatment decision-making and 
discussions between clinicians and patients.
This study is also a proof-of-principle for other coun-
tries in terms of illustrating the strength of large data-
bases. Colon cancer is a common cancer worldwide 
[10]. Particularly in China, the incidence of colon can-
cer is anticipated to increase significantly over time, 
and the burden of this disease and its effect on society 
are expected to grow exponentially, especially given the 
longer lifespan of patients that has resulted from recent 
diagnostic and therapeutic advances [11, 12]. Although 
clinical trials are offered globally, the number of phase III 
trials available in China often pales in comparison to the 
number available in Western countries. Reasons for this 
disparity are numerous and may include various clinical 
and systemic factors, such as infrastructure and resource 
constraints or concerns regarding the risks of adverse 
events that may be more prevalent or unique among 
Asian patients.
As in many other countries, in China participation 
in clinical trials is suboptimal. It is estimated that only 
2%–4% of patients in China with cancer ultimately con-
sent to enroll in clinical trials, even when studies are 
available and offered to eligible patients [13]. This find-
ing has been attributed in part to inherent cultural beliefs 
that regard clinical trials as socially undesirable [14]. 
Interestingly, these negative perceptions of clinical trials 
have been shown to dissipate after effective educational 
interventions and open discussions with physicians [15]. 
As such, our nomogram may aid clinicians in their con-
versations with patients.
Because large clinical trials are not always accessible, 
and since important research questions almost always 
require adequate sample sizes to address well, pooling 
data from either population-based settings or clinical 
trial settings is an effective strategy for cancer outcomes 
research. Currently, the ACCENT database comprises 
patient-level data from over 25 adjuvant colon cancer 
clinical trials from North America and Europe. When 
the outcome of interest, such as early mortality, is rela-
tively rare, pooling data can add validity to the analysis 
and strength to its findings. Presently, China is not part 
of similar database-driven initiatives, but pooling of such 
data may prove to be an invaluable resource for Asian 
patients [16]. Databases such as those available at BCCA 
or via ACCENT are excellent examples of the power of 
pooled data. The creation of similar databases of Asian 
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patients should be strongly encouraged to make inves-
tigations of rare but clinically pertinent endpoints more 
feasible [17].
Conclusions
We developed and validated a ready-to-use and user-
friendly nomogram to assist potential clinical trial par-
ticipants with benefit-to-risk assessments. The ability to 
quantitatively and objectively predict the risk of harm 
and early death can better facilitate the patient-physi-
cian dialogue and the informed consent process. For this 
study, we used a large database of pooled individual-level 
data from patients who previously participated in clini-
cal trials [6]. Having access to such a database of pooled 
information will continue to be invaluable for investiga-
tors who address other important research questions. 
As China and other Asian countries continue to conduct 
oncology clinical trials, efforts to collate patient-level 
information from these studies into a large data reposi-
tory should be strongly considered since pooled data can 
increase future capacity for cancer outcomes research, 
which, in turn, can enhance patient-physician discus-
sions and optimize clinical care. More importantly, the 
development of a database initiative specific to Chinese 
patients will further enable researchers to study aspects 
of cancer care that may be unique to Asia.
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